



The relative strengths and weaknesses of BridgeBio Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BridgeBio Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 130% points. The greatest weakness of BridgeBio Pharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is -150%, being 153% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	568,622
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	60,385
Liabilities, Non-Current	95,318
Other Assets	57,432
Other Compr. Net Income	28,252
Other Expenses	2,500
Other Liabilities	0
Other Net Income	-22,345
Property and Equipment	5,625
Research and Development	209,947
Revenues	40,560
Selling, General and Administrative Expense	94,353

Output Variable	Value in 1000 USD
Assets	631,679
Liabilities	155,703
Expenses	306,800
Stockholders Equity	475,976
Net Income	-288,585
Comprehensive Net Income	-274,459
Economic Capital Ratio	-150%